Quick Search:         Advanced Search
Chinese Version
Online office
Journal Online
Download
Top
Links
林春龙,张珍祥,徐永健,倪望.青心酮对慢性阻塞性肺病患者血流动力学及血浆心钠素和环磷酸苷类水平的影响[J].,1995,(3):131-133
青心酮对慢性阻塞性肺病患者血流动力学及血浆心钠素和环磷酸苷类水平的影响
Effects of Dihydroxyacetophenone on Pulmonary Hemodynamics and Plasma ANP as well as cAMP/cGMP Level in Patients with Chronic Obstructive Pulmonary Disease
  
DOI:
中文关键词:  青心酮  心钠素  环磷酸腺苷  环磷酸鸟苷  慢性阻塞性肺病  肺血流动力学
英文关键词:dihydroxyacetophenone  atrial natriuretic peptide  cyclo-adenosinemonophosphate  cyclic guanosine monophosphate  chronic obstructive pulmonary disease  pulmonary hemodynamics
基金项目:国家“八·五”重点科技攻关课题
Author NameAffiliation
Lin Chun-long 同济医科大学附属同济医院呼吸疾病研究室 
Zhang Zhen-xiang 同济医科大学附属同济医院呼吸疾病研究室 
Xu Yong-jian 同济医科大学附属同济医院呼吸疾病研究室 
倪望 同济医科大学附属同济医院呼吸疾病研究室 
Hits: 1419
Download times: 1147
中文摘要:
      为了解青心酮对慢性阻塞性肺病(慢阻肺)患者血流动力学的影响,用右心漂浮导管检测了11例慢阻肺患者应用青心酮前、后血流动力学某些参数,同时采用放射免疫分析法测定了血浆心钠素及环磷酸苷类水平。结果:静脉注射青心酮后,肺动脉平均压及肺循环阻力、体循环阻力均下降(P<0.05).体动脉压及动脉血气指标无明显变化(P>0.05),心输出量在正常范围内增加。血浆心钠素、环磷酸鸟苷水平下降(P<0.01,P<0.05)。表明青心酮可能通过调节环磷酸腺苷、环磷酸鸟苷的比值而达到扩血管目的,其心钠素降低可能是一种继发性反应。
英文摘要:
      In order to study the effect of dihydroxyacetophenone (DHAP) on pulmonary hemodynamics and its relationship to plasma ANP as well as cAMP/cGMP level in chronic obstructive pulmonary disease (COPD),11 COPD patients were examined with the right heart catheterisation, and the plasma ANP and cAMP/cGMP were measured with radioimmunoassay at the same time. The results showed that intravenous given DHAP 640mg could decrease mean pulmonary arterial pressure, pulmonary vascular resistance and systemic vascular resistance (P<0. 05), but increase the cardiac output from 4.10±1.08 L/min to 5.13±1.19 L/min (P>0.05) and not affect systemic arterial pressure (P>0. 05) as well as blood gas analysis; it also reduce the plasma ANP and cGMP level from 0. 73±0 . 42 pg/ml to 0. 41±0 . 33 pg/ml (P<0.01) and from 9. 82±5. 75 pm/ml to 8. 01±4.80 pm/ml (P<0.05) respectively, but did not affect the plasma cAMP level (P>0.05).It is suggested that DHAP may relax pulmonary vessels by regulating the ratio of cAMP to cGMP,and the lowering of plasma ANP level might be a secondary reaction. So we consider that DHAP is a fast-acting,safe and potential drug in treating pulmonary arterial hpertension by COPD.
View Full Text  View/Add Comment  Download reader